Xiidra Solution/ Drops
NDC 24208-911
Product Information
Xiidra (lifitegrast) is a NDA-approved product labeled by Bausch & Lomb Incorporated. This medication is used to treat dry eye disease. It is supplied as a solution/ drops for ophthalmic administration. This product entry covers the primary NDC 24208-911 and 2 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 24208-911?
What are the uses of this product?
What are Active Ingredients of this product?
- LIFITEGRAST 50 mg/mL - An LFA-1 (LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1) antagonist that is used in the treatment of DRY EYE SYNDROMES.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- LIFITEGRAST (UNII: 038E5L962W)
- LIFITEGRAST (UNII: 038E5L962W) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- SODIUM CHLORIDE (UNII: 451W47IQ8X)
- SODIUM PHOSPHATE, DIBASIC, ANHYDROUS (UNII: 22ADO53M6F)
- SODIUM THIOSULFATE (UNII: HX1032V43M)
- SODIUM HYDROXIDE (UNII: 55X04QC32I)
- HYDROCHLORIC ACID (UNII: QTT17582CB)
- WATER (UNII: 059QF0KO0R)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1801835 - lifitegrast 5 % Ophthalmic Solution
- RxCUI: 1801835 - lifitegrast 50 MG/ML Ophthalmic Solution
- RxCUI: 1801840 - xiidra 5 % Ophthalmic Solution
- RxCUI: 1801840 - lifitegrast 50 MG/ML Ophthalmic Solution [Xiidra]
- RxCUI: 1801840 - xiidra 50 MG/ML Ophthalmic Solution
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.